Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine

Pharma Intelligence Podcasts

Sep 21, 202640:09Business

In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into real medicines. They discuss Rubedo’s lead...

Related Episodes

Continue listening to more episodes from Pharma Intelligence Podcasts.

Assessing the current dealmaking environment for psychedelic medicine.

Sep 18, 2026 - 19:41

Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent deve...

Digital Health Roundup: Oura Plans IPO, FDA’s Home Health, Digital Tools For Alzheimer’s Detection

Sep 16, 2026 - 21:02

In this month: Marion Webb highlights Oura’s IPO, new partnerships, and a class-action lawsuit. George Un...

Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization

Sep 15, 2026 - 36:13

"Personalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions...

Scaling Self-Care In Asia Pacific, With APSMI's Rachmadi Joesoef and Anama O'Reilly

Sep 15, 2026 - 37:06

In this episode of Over the Counter, now also in video, HBW Insight talks to Rachmadi Joesoef, APSMI chai...

Drug Fix: Increasing US FDA Leadership Stability And Where All The Adcomms Have Gone

Sep 11, 2026 - 35:48

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Editor-in-Chief Nielsen Hobbs and...

Strategic Intent: Evolving Requirements Of Life Sciences Leadership

Sep 8, 2026 - 21:17

In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement c...

Drug Fix: US FDA Commissioner Nominee Heidi Overton’s Resume And COVID-19 Vaccine Trial Changes

Sep 4, 2026 - 38:09

Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman, and...

Proof Of Concept: How A Charity Bridges Lab And Clinic

Sep 4, 2026 - 21:27

Cancer Research UK is best known for funding science. But its commercial arm, Cancer Research Horizons, d...